Biallelic loss of CDKN2A is associated with poor response to treatment in pediatric acute lymphoblastic leukemia

References

• Mullighan CG, Goorha S, Radtke I, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007;446:758–764.
   PubMed Web of Science ®Google Scholar
• Mullighan CG. The molecular genetic makeup of acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2012;2012:389–396.
   PubMed Web of Science ®Google Scholar
• Hunger SP, Mullighan CG. Redefining ALL classification: toward detecting high-risk ALL and implementing precision medicine. Blood. 2015;125:3977–3987.
   PubMed Web of Science ®Google Scholar
• Moorman AV. New and emerging prognostic and predictive genetic biomarkers in B-cell precursor acute lymphoblastic. Leukemia. 2015;9:7–16.
   Google Scholar
• Moorman AV, Schwab C, Ensor HM, et al. IGH@ translocations, CRLF2 deregulation, and microdeletions in adolescents and adults with acute lymphoblastic leukemia. J Clin Oncol. 2012;30:3100–3108.
   PubMed Web of Science ®Google Scholar
• Moorman AV, Enshaei A, Schwab C, et al. A novel integrated cytogenetic and genomic classification refines risk stratification in pediatric acute lymphoblastic. Leukemia. 2015;124:1434–1445.
   Google Scholar
• Schwab CJ, Chilton L, Morrison H, et al. Genes commonly deleted in childhood B-cell precursor acute lymphoblastic leukemia: Association with cytogenetics and clinical features. Haematologica. 2013;98:1081–1088.
   PubMed Web of Science ®Google Scholar
• Kim WY, Sharpless NE. The regulation of INK4/ARF in cancer and aging. Cell. 2006;127:265–275.
   PubMed Web of Science ®Google Scholar
• Raschke S, Balz V, Efferth T, et al. Homozygous deletions of CDKN2A caused by alternative mechanisms in various human cancer cell lines. Genes Chromosomes Cancer. 2005;42:58–67.
   PubMed Web of Science ®Google Scholar
• Novara F, Beri S, Bernardo ME, et al. Different molecular mechanisms causing 9p21 deletions in acute lymphoblastic leukemia of childhood. Hum Genet. 2009;126:511–520.
   PubMed Web of Science ®Google Scholar
• Schiffman JD, Wang Y, Mcpherson LA, et al. Molecular inversion probes reveal patterns of 9p21 deletion and copy number aberrations in childhood leukemia. Cancer Genet Cytogenet. 2009;1:9–18.
   Google Scholar
• Sulong S, Moorman AV, Irving JE, et al. A comprehensive analysis of the CDKN2A gene in childhood acute lymphoblastic leukemia reveals genomic deletion, copy number neutral loss of heterozygosity, and association with specific cytogenetic subgroups. Blood. 2009;113:100–107.
   PubMed Web of Science ®Google Scholar
• Sarhadi VK, Lahti L, Scheinin I, et al. Targeted resequencing of 9p in acute lymphoblastic leukemia yields concordant results with array CGH and reveals novel genomic alterations. Genomics. 2013;102:182–188.
   PubMed Web of Science ®Google Scholar
• Calero Moreno TM, Gustafsson G, Garwicz S, et al. Deletion of the Ink4-locus (the p16ink4a, p14ARF and p15ink4b genes) predicts relapse in children with ALL treated according to the Nordic protocols NOPHO-86 and NOPHO-92. Leukemia. 2002;16:2037–2045.
   PubMed Web of Science ®Google Scholar
• Gutierrez MI, Siraj AK, Bhargava M, et al. Concurrent methylation of multiple genes in childhood ALL: Correlation with phenotype and molecular subgroup. Leukemia. 2003;17:1845–1850.
   PubMed Web of Science ®Google Scholar
• Tsellou E, Troungos C, Moschovi M, et al. Hypermethylation of CpG islands in the promoter region of the p15INK4B gene in childhood acute leukaemia. Eur J Cancer. 2005;41:584–589.
   PubMed Web of Science ®Google Scholar
• Mirebeau D, Acquaviva C, Suciu S, et al. The prognostic significance of CDKN2A, CDKN2B and MTAP inactivation in B-lineage acute lymphoblastic leukemia of childhood. Results of the EORTC studies 58881 and 58951Haematologica. 2006;91:881–885.
   PubMed Web of Science ®Google Scholar
• Usvasalo A, Savola S, Räty R, et al. CDKN2A deletions in acute lymphoblastic leukemia of adolescents and young adults: an array CGH study. Leuk Res. 2008;32:1228–1235.
   PubMed Web of Science ®Google Scholar
• Kim M, Choi JE, She CJ, et al. PAX5 deletion is common and concurrently occurs with CDKN2A deletion in B-lineage acute lymphoblastic leukemia. Blood Cells, Mol Dis. 2011;47:62–66.
   PubMed Web of Science ®Google Scholar
• Krentz S, Hof J, Mendioroz A, et al. Prognostic value of genetic alterations in children with first bone marrow relapse of childhood B-cell precursor acute lymphoblastic leukemia. Leukemia. 2012;2:295–304.
   Google Scholar
• Wong IH, Ng MH, Huang DP, et al. Aberrant p15 promoter methylation in adult and childhood acute leukemias of nearly all morphologic subtypes: potential prognostic implications. Blood. 2000;95:1942–1949.
   PubMed Web of Science ®Google Scholar
• van Zutven LJCM, van Drunen E, de Bont JM, et al. CDKN2 deletions have no prognostic value in childhood precursor-B acute lymphoblastic leukemia. Leukemia. 2005;19:1281–1284.
   PubMed Web of Science ®Google Scholar
• Kim M, Yim SH, Cho NS, et al. Homozygous deletion of CDKN2A (p16, p14) and CDKN2B (p15) genes is a poor prognostic factor in adult but not in childhood B-lineage acute lymphoblastic leukemia: a comparative deletion and hypermethylation study. Cancer Genet Cytogenet. 2009;195:59–65.
   PubMed Web of Science ®Google Scholar
• Ribera J, Morgades M, Zamora L, et al. Prognostic significance of copy number alterations in adolescent and adult patients with precursor B acute lymphoblastic leukemia enrolled in PETHEMA protocols. Cancer. 2015;21:3809–3817.
   Web of Science ®Google Scholar
• Mullighan CG, Phillips LA, Su X, et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science. 2008;322:1377–1380.
   PubMed Web of Science ®Google Scholar
• Schwab CJ, Jones LR, Morrison H, et al. Evaluation of multiplex ligation-dependent probe amplification as a method for the detection of copy number abnormalities in B-cell precursor acute lymphoblastic leukemia. Genes Chromosomes Cancer. 2010;49:1104–1113.
   PubMed Web of Science ®Google Scholar
• Stary J, Zimmermann M, Campbell M, et al. Intensive chemotherapy for childhood acute lymphoblastic leukemia: results of the randomized intercontinental trial ALL IC-BFM 2002. J Clin Oncol. 2014;32:174–184.
   PubMed Web of Science ®Google Scholar
• van Dongen JJM, Lhermitte L, Böttcher S, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia. 2012;26:1908–1975.
   PubMed Web of Science ®Google Scholar
• Kalina T, Flores-Montero J, van der Velden VHJ, et al. EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia. 2012;26:1986–2010.
   PubMed Web of Science ®Google Scholar
• Gardiner RB, Morash BA, Riddell C, et al. Using MS-MLPA as an efficient screening tool for detecting 9p21 abnormalities in pediatric acute lymphoblastic leukemia. Pediatr Blood Cancer. 2012;58:852–859.
   PubMed Web of Science ®Google Scholar
• Iacobucci I, Ferrari A, Lonetti A, et al. CDKN2A/B alterations impair prognosis in adult BCR-ABL1 – positive acute lymphoblastic leukemia patients. Clin Cancer Res. 2011;17:7413–7424.
   PubMed Web of Science ®Google Scholar
• Graf Einsiedel H, Taube T, Hartmann R, et al. Prognostic value of p16(INK4a) gene deletions in pediatric acute lymphoblastic leukemia. Blood. 2001;97:4002–4004.
   PubMed Web of Science ®Google Scholar
• van Dongen JJM, van der Velden VHJ, Brüggemann M, et al. Minimal residual disease (MRD) diagnostics in acute lymphoblastic leukemia (ALL): need for sensitive, fast and standardized technologies. Blood. 2015;26:3996–4009.
   Web of Science ®Google Scholar
• Yang JJ, Bhojwani D, Yang W, et al. Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia. Blood. 2008;112:4178–4183.
   PubMed Web of Science ®Google Scholar